Cytokine Response and Survival of Mice Immunized with an Adenovirus Expressing Bacillus anthracis Protective Antigen Domain 4
Open Access
- 1 February 2006
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 74 (2) , 1009-1015
- https://doi.org/10.1128/iai.74.2.1009-1015.2006
Abstract
Adenovirus vectors are promising for use in vaccinating against potential agents of bioterrorism and emerging infections because of their proven safety in humans and their ability to elicit rapid immune responses. Here, we describe the construction and evaluation of an adenovirus vaccine expressing domain 4 of Bacillus anthracis protective antigen, Ad.D4. Ad.D4 elicited antibodies to protective antigen 14 days after a single intramuscular injection, which were further increased upon boosting. Furthermore, two doses of Ad.D4 4 weeks apart were sufficient to protect 67% of mice from toxin challenge. Additionally, we have characterized the release of inflammatory cytokines from vaccinated mice after lethal-toxin challenge. We demonstrate that interleukin 1β (IL-1β) levels in mice that survive lethal toxin challenge are similar to levels in nonsurvivors and that IL-6 levels are higher in survivors than in nonsurvivors. These findings suggest that lethal-toxin-mediated death may not be a direct result of inflammatory-cytokine release.Keywords
This publication has 46 references indexed in Scilit:
- Immunogenicity of Recombinant Protective Antigen and Efficacy against Aerosol Challenge with AnthraxInfection and Immunity, 2005
- Combining Anthrax Vaccine and Therapy: a Dominant-Negative Inhibitor of Anthrax Toxin Is Also a Potent and Safe Immunogen for VaccinesInfection and Immunity, 2005
- Analysis of the Interaction of the Adenovirus L1 52/55-Kilodalton and IVa2 Proteins with the Packaging Sequence In Vivo and In VitroJournal of Virology, 2005
- Protective Immunity Evoked Against Anthrax Lethal Toxin After a Single Intramuscular Administration of an Adenovirus-Based Vaccine Encoding Humanized Protective AntigenHuman Gene Therapy, 2003
- Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primatesNature, 2003
- Requirement of the Adenovirus IVa2 Protein for Virus AssemblyJournal of Virology, 2003
- Pseudopackaging of Adenovirus Type 5 Genomes into Capsids Containing the Hexon Proteins of Adenovirus Serotypes B, D, or EJournal of Virology, 2001
- Role of Toxin Functional Domains in Anthrax PathogenesisInfection and Immunity, 2000
- AnthraxNew England Journal of Medicine, 1999
- Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5Journal of General Virology, 1977